IP Library Granted Patent US 12,129,276
Granted Patent B2
US 12,129,276 · App. 18/116,557 · Granted Oct 29, 2024

Oxysterols and methods of use thereof

Inventors: Boyd L. Harrison (Princeton Junction, NJ); Gabriel Martinez Botella (Wayland, MA); Albert Jean Robichaud (Boston, MA); Francesco G. Salituro (Marlborough, MA)
Assignee: SAGE THERAPEUTICS, INC.
C07J9/00A61K9/0019A61K9/0095A61K9/2063A61K9/4866A61K31/575C07J9/005C07J13/005C07J13/007C07J31/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,129,276
App. No.
18/116,557
Granted
Oct 29, 2024
Kind
B2
Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7 , and R 8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Claims (44)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, or heterocyclyl;

each of R 2a and R 2b is independently hydrogen, C 1 -C 6 alkyl, halo, cyano,—OR A , or —NR B R C , or

R 2a and R 2b together with the carbon atom to which they are attached form a 3-7 membered ring;

each of R 4a and R 4b is independently absent, hydrogen, C 1 -C 6 alkyl, or halo;

X is —C(R X ) 2 — or —O—, wherein R X is independently hydrogen, halo, or one R X group and R 5b are joined to form a double bond;

Y is —OR Y , wherein R Y is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)R A , —C(O)OR A , —C(O)NR B R C , or —S(O) 2 R D ;

each instance of R 5a and R 5b is independently hydrogen, halo, or C 1 -C 6 alkyl;

each of R 6a and R 6b is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl, or

R 6a and R 6b , taken together with the carbon atom to which they are attached, form a 3-6 membered ring; or

R 5a and R 6a , together with the carbon atoms to which they are attached, form a 3-6-membered ring; and

R 7 is absent or hydrogen in the alpha configuration;

R 8 is hydrogen, halo, C 1 - 6 alkyl, carbocyclyl, or —OR A ;

represents a single or double bond, wherein when one is a double bond, the other is a single bond;

wherein when the between —CR 7 and —CR 4a R 4b is a double bond, then one of R 4a or R 4b is absent; and

when one of the is a double bond, R 7 is absent;

R A is hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

each of R B and R C is independently hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a 3-7-membered ring; and

R D is hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted C 1 - 3 alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted C 1 - 3 alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2a or R 2a is hydrogen.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4a is hydrogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is —CH 2 —.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 8 is substituted or unsubstituted C 1 - 3 alkyl.

8. The compound of claim 1 , wherein the compound of Formula (I) is a compound of Formula (II):

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 , wherein the compound of Formula (II) is a compound of Formula (II-A):

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 8 , wherein the compound of Formula (II) is a compound of Formula (II-B):

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5a or R 5b is hydrogen.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6a is a substituted or unsubstituted C 1 - 3 alkyl.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6a is a substituted or unsubstituted C 2 - 4 alkyl, substituted or unsubstituted C 2 - 3 alkenyl, substituted or unsubstituted C 2 - 3 alkynyl, or substituted or unsubstituted carbocyclyl.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6b is substituted or unsubstituted C 1 - 3 alkyl.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6a and R 6b , taken together with the atom to which they are attached, form a 3-6 membered ring.

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R Y is substituted or unsubstituted C 1 - 3 alkyl.

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R Y is substituted or unsubstituted heterocyclyl.

18. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. The compound of claim 18 , wherein the compound is:

Assignments (3)
CHANGE OF NAME Recorded Mar 17, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075109/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2025
From: ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ; SALITURO, FRANCESCO G.; HARRISON, BOYD L.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071333/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2024
From: HARRISON, BOYD L.; MARTINEZ BOTELLA, GABRIEL; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 067846/0126 →
Continuity (6)
Continuation 16902730 · Jun 16, 2020
Continuation 16028790 · Jul 6, 2018
Continuation 15319504
Provisional Application 62107236 · Jan 23, 2015
Provisional Application 62014014 · Jun 18, 2014
Related Publication 20230348526A1 · Nov 2, 2023
Cited By (2)
US 12,448,409 US 12,540,157